Boston Scientific Files 8-K: Other Events & Financials

Ticker: BSX · Form: 8-K · Filed: 2025-01-16T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: BSX

TL;DR

BSX filed an 8-K on Jan 16, 2025, covering 'Other Events' and financial exhibits.

AI Summary

On January 16, 2025, Boston Scientific Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. Specific details regarding new events or financial figures are not elaborated in the provided text, but the filing serves as a formal notification to the SEC.

Why It Matters

This 8-K filing by Boston Scientific Corporation signals important updates or disclosures to investors and the market regarding the company's financial statements and other significant events.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain immediate negative news or significant financial distress.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by Boston Scientific Corporation in this 8-K filing?

The provided text does not specify the details of the 'Other Events'; it only indicates that this item is part of the filing.

What is the significance of the "Financial Statements and Exhibits" section in this filing?

This section indicates that updated or relevant financial statements and supporting exhibits are being provided to the SEC as part of the 8-K report.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on January 16, 2025.

Where is Boston Scientific Corporation incorporated?

Boston Scientific Corporation is incorporated in Delaware.

What is the business address of Boston Scientific Corporation?

The business address is 300 Boston Scientific Way, Marlborough, Massachusetts, 01752-1234.

From the Filing

0000885725-25-000003.txt : 20250116 0000885725-25-000003.hdr.sgml : 20250116 20250116162610 ACCESSION NUMBER: 0000885725-25-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20250116 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250116 DATE AS OF CHANGE: 20250116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 25535962 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20250116.htm 8-K bsx-20250116 0000885725 false 0000885725 2025-01-16 2025-01-16 0000885725 us-gaap:CommonStockMember 2025-01-16 2025-01-16 0000885725 bsx:SeniorNotedue2027Member 2025-01-16 2025-01-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): January 16, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 8.01 Other Events. On January 8, 2025, the United States District Court for the District of Massachusetts (the “Court”) issued an order (the “Preliminary Approval Order”) granting preliminary approval to a proposed settlement of two shareholder derivative actions and de

View on Read The Filing